Citadel Advisors’s Akebia Therapeutics AKBA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.93M | Sell |
1,390,067
-3,275,470
| -70% | -$4.5M | ﹤0.01% | 6131 |
|
|
2025
Q4 | $7.51M | Buy |
4,665,537
+1,479,711
| +46% | +$3.1M | ﹤0.01% | 3656 |
|
|
2025
Q3 | $8.7M | Buy |
3,185,826
+868,536
| +37% | +$2.89M | ﹤0.01% | 3477 |
|
|
2025
Q2 | $8.43M | Sell |
2,317,290
-1,329,619
| -36% | -$3.65M | ﹤0.01% | 3280 |
|
|
2025
Q1 | $7M | Buy |
3,646,909
+2,264,763
| +164% | +$4.62M | ﹤0.01% | 3369 |
|
|
2024
Q4 | $2.63M | Buy |
+1,382,146
| New | +$2.4M | ﹤0.01% | 5074 |
|
|
2024
Q3 | – | Sell |
-214,669
| Closed | -$287K | – | 14154 |
|
|
2024
Q2 | $219K | Buy |
214,669
+131,435
| +158% | +$162K | ﹤0.01% | 9742 |
|
|
2024
Q1 | $152K | Sell |
83,234
-105,360
| -56% | -$168K | ﹤0.01% | 10745 |
|
|
2023
Q4 | $234K | Buy |
+188,594
| New | +$192K | ﹤0.01% | 9638 |
|
|
2023
Q3 | – | Sell |
-965
| Closed | -$1.24K | – | 14225 |
|
|
2023
Q2 | $883 | Buy |
+965
| New | +$931 | ﹤0.01% | 14029 |
|
|
2023
Q1 | – | Sell |
-13,397
| Closed | -$10.2K | – | 14651 |
|
|
2022
Q4 | $7.73K | Sell |
13,397
-287,777
| -96% | -$90.2K | ﹤0.01% | 13803 |
|
|
2022
Q3 | $95K | Sell |
301,174
-156,129
| -34% | -$61.3K | ﹤0.01% | 11131 |
|
|
2022
Q2 | $162K | Buy |
457,303
+2,306
| +0.5% | +$968 | ﹤0.01% | 10905 |
|
|
2022
Q1 | $326K | Sell |
454,997
-110,900
| -20% | -$237K | ﹤0.01% | 10401 |
|
|
2021
Q4 | $1.28M | Buy |
565,897
+426,399
| +306% | +$1.16M | ﹤0.01% | 7300 |
|
|
2021
Q3 | $402K | Sell |
139,498
-65,222
| -32% | -$186K | ﹤0.01% | 10398 |
|
|
2021
Q2 | $776K | Sell |
204,720
-167,395
| -45% | -$563K | ﹤0.01% | 9021 |
|
|
2021
Q1 | $1.26M | Sell |
372,115
-608,146
| -62% | -$2.19M | ﹤0.01% | 7527 |
|
|
2020
Q4 | $2.75M | Buy |
980,261
+563,132
| +135% | +$1.64M | ﹤0.01% | 4728 |
|
|
2020
Q3 | $1.05M | Buy |
417,129
+368,387
| +756% | +$3.23M | ﹤0.01% | 5948 |
|
|
2020
Q2 | $662K | Sell |
48,742
-170,539
| -78% | -$1.76M | ﹤0.01% | 6570 |
|
|
2020
Q1 | $1.66M | Sell |
219,281
-688,939
| -76% | -$5.36M | ﹤0.01% | 4444 |
|
|
2019
Q4 | $5.74M | Buy |
908,220
+537,470
| +145% | +$2.55M | ﹤0.01% | 2917 |
|
|
2019
Q3 | $1.45M | Buy |
370,750
+268,218
| +262% | +$1.15M | ﹤0.01% | 4974 |
|
|
2019
Q2 | $497K | Buy |
102,532
+70,086
| +216% | +$399K | ﹤0.01% | 6829 |
|
|
2019
Q1 | $265K | Sell |
32,446
-1,407,296
| -98% | -$9.66M | ﹤0.01% | 7792 |
|
|
2018
Q4 | $7.96M | Buy |
1,439,742
+447,966
| +45% | +$3.51M | ﹤0.01% | 2163 |
|
|
2018
Q3 | $8.76M | Buy |
991,776
+371,440
| +60% | +$3.32M | ﹤0.01% | 2271 |
|
|
2018
Q2 | $6.19M | Buy |
620,336
+391,022
| +171% | +$3.91M | ﹤0.01% | 2487 |
|
|
2018
Q1 | $2.19M | Buy |
+229,314
| New | +$3.21M | ﹤0.01% | 3604 |
|
|
2017
Q3 | – | Sell |
-20,470
| Closed | -$315K | – | 7476 |
|
|
2017
Q2 | $294K | Sell |
20,470
-45,115
| -69% | -$572K | ﹤0.01% | 5946 |
|
|
2017
Q1 | $603K | Buy |
65,585
+26,289
| +67% | +$257K | ﹤0.01% | 4719 |
|
|
2016
Q4 | $409K | Buy |
+39,296
| New | +$338K | ﹤0.01% | 5220 |
|
|
2016
Q3 | – | Sell |
-25,818
| Closed | -$193K | – | 7182 |
|
|
2016
Q2 | $193K | Buy |
25,818
+4,699
| +22% | +$41K | ﹤0.01% | 5862 |
|
|
2016
Q1 | $190K | Buy |
+21,119
| New | +$171K | ﹤0.01% | 5674 |
|
|
2015
Q4 | – | Sell |
-63,802
| Closed | -$616K | – | 8679 |
|
|
2015
Q3 | $616K | Buy |
63,802
+55,340
| +654% | +$508K | ﹤0.01% | 4497 |
|
|
2015
Q2 | $87K | Buy |
+8,462
| New | +$72.2K | ﹤0.01% | 7216 |
|
|
2014
Q2 | – | Sell |
-18,448
| Closed | -$361K | – | 7933 |
|
|
2014
Q1 | $361K | Buy |
+18,448
| New | +$389K | ﹤0.01% | 4798 |
|
Other funds holding AKBA
VCM
VPM
Citadel Advisors's AKBA Position: Q1 2026 in Review
Citadel Advisors reduced its Akebia Therapeutics (AKBA) stake by 70% in Q1 2026, selling an estimated $4.5M and leaving 1,390,067 shares worth $1.93M. The position accounts for ﹤0.01% of the portfolio, ranked #6131.
Citadel Advisors first reported a position in AKBA in Q1 2014 and has held it in 38 quarters since. The position peaked at $8.76M in Q3 2018. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.
- Citadel Advisors held 1,390,067 shares of Akebia Therapeutics worth $1.93M as of Q1 2026.
- Citadel Advisors sold 3,275,470 Akebia Therapeutics shares in Q1 2026, an estimated $4.5M.
- Akebia Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #6131 holding.
- Citadel Advisors first reported a position in Akebia Therapeutics in Q1 2014 and has held it in 38 quarters since.
- Citadel Advisors's Akebia Therapeutics position peaked at $8.76M in Q3 2018.
- 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.